Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
Chen-style Tai Chi in Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease
Verified date | April 2018 |
Source | Laval University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the effects of Chen-style Tai Chi compared to conventional exercise in pulmonary rehabilitation for COPD patients. Half of participants will receive the Chen-style Tai Chi intervention, while the other half will receive the conventional exercise intervention. Both groups will receive the same eduction and support during pulmonary rehabilitation.
Status | Completed |
Enrollment | 44 |
Est. completion date | July 1, 2017 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - FEV1 between 30 and 80% of the predicted normal values - FEV1/FVC ratio < 70% Exclusion Criteria: - Patients with very severe COPD (GOLD IV); - Patients that had a COPD exacerbations within the preceding 2 weeks of the baseline assessments; - Significant hypoxemia at rest or during exercise (SpO2 <85%); - Already following a rehabilitation program; - Have physical limitations that compromises participation to a Tai chi and a conventional exercise program |
Country | Name | City | State |
---|---|---|---|
Canada | Institut universitaire de cardiologie et de pneumologie de Québec | Quebec |
Lead Sponsor | Collaborator |
---|---|
Laval University | Maltais, Francois, M.D., Saey, Didier, M.D. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline dyspnea at 12 weeks | Dyspnea will be assessed using the chronic respiratory questionnaire (CRQ) | Baseline, 12 weeks | |
Secondary | Change from baseline lung function at week 12 (Spirometry and whole-body plethysmography) | Spirometry and whole-body plethysmography will be used for baseline and post-training (12 weeks) lung function testing. | Baseline, 12 weeks | |
Secondary | Change from baseline walking distance at 12 weeks (distance walked during the six-minute walk test) | The distance walked during the six-minute walk test will be used to evaluate the functional exercise capacity of all participants at baseline and post-rehabilitation. | Baseline, 12 weeks | |
Secondary | Change from baseline exercise capacity at 12 weeks(Endurance time during a constant work rate bicycle ergometry exercise test) | Endurance time during a constant work rate bicycle ergometry exercise test will be used to evaluate the exercise capacity of all participants at baseline and post-rehabilitation. | Baseline, 12 weeks | |
Secondary | Change from baseline isokinetic quadriceps muscle function at 12 weeks | Voluntary isokinetic quadriceps muscle function will be determined by quantification of force, endurance, and fatigability of the dominant quadriceps during a series of 30 repetitions at an angular velocity of 90°/s of a knee extension test. | Baseline, 12 weeks | |
Secondary | Change from baseline isometric quadriceps muscle strength at 12 weeks (force of the dominant quadriceps will be measured during a single magnetic stimulation of the femoral nerve) | The force of the dominant quadriceps will be measured during a single magnetic stimulation of the femoral nerve (Twitch force of the quadriceps [Twq]) and during a maximum voluntary contraction (MVC). | Baseline, 12 weeks | |
Secondary | Change from baseline physical activity at 12 weeks (participants will be equipped with a physical activity monitor) | To monitor physical activity, participants will be equipped with a physical activity monitor. The device will monitor the daily energy expenditure, the duration of physical activities above the pre-determined intensity level (Metabolic Equivalent of Task (MET) >3), and also the total daily number of steps. | Baseline, 12 weeks | |
Secondary | Change from baseline quality of life (QoL) at 12 weeks | In addition to dyspnea (primary outcome), the CRQ will be used also to measure other physical-functional limitations due to COPD with questions related to fatigue and energy levels. | Baseline, 12 weeks | |
Secondary | Change from baseline health status at 12 weeks (determined with the COPD Assessment test (CAT). | Impact of COPD on a person's life will be determined with the COPD Assessment test (CAT). | Baseline, 12 weeks | |
Secondary | Change from baseline balance (Berg Balance Test (BBT) at 12 weeks | The Berg Balance Test (BBT) will be used to evaluate the effect of the interventions on patient's balance. | Baseline, 12 weeks | |
Secondary | Change from baseline of composite serum and plasma biomarkers at 12 weeks | During the baseline assessment and after the rehabilitation program, blood samples from patients will be taken in order to investigate the effect of the interventions on different biomarkers related to systemic inflammation. | Baseline, 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |